Leerink Partnrs Has Negative Outlook of ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Leerink Partnrs decreased their FY2025 earnings estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($1.14) for the year, down from their previous estimate of ($1.02). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.36) EPS and FY2029 earnings at ($0.67) EPS.

Separately, Guggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ ELDN opened at $3.41 on Wednesday. The company has a market capitalization of $204.20 million, a price-to-earnings ratio of -1.70 and a beta of 0.80. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54. The business has a 50 day simple moving average of $4.13 and a 200-day simple moving average of $3.88.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter in the previous year, the business posted ($1.00) earnings per share.

Hedge Funds Weigh In On Eledon Pharmaceuticals

A number of large investors have recently bought and sold shares of ELDN. Inspire Investing LLC acquired a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth approximately $802,000. Geode Capital Management LLC increased its position in Eledon Pharmaceuticals by 9.7% in the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after buying an additional 33,569 shares during the period. Kera Capital Partners Inc. bought a new stake in Eledon Pharmaceuticals in the fourth quarter valued at $106,000. Boothbay Fund Management LLC acquired a new position in shares of Eledon Pharmaceuticals during the fourth quarter valued at $1,409,000. Finally, First Light Asset Management LLC bought a new position in shares of Eledon Pharmaceuticals during the fourth quarter worth about $9,595,000. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).